In addition, the median PFS of anlotinib was also numerically similar to 5.4-7.1 months of pembrolizumab monotherapy in the driver-gene wild-type NSCLC with different PD-L1 expressions (24). Here, CD274 is linked to non-small cell lung carcinoma.